Viewing data from:

DIFFERIN EPIDUO

NDA

ADAPALENE; BENZOYL PEROXIDE | N220736 | GALDERMA LABORATORIES LP

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 22, 2026	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.1%;2.5%

RLD

0 patents0 exclusivities▴

GEL;TOPICAL | Approved: May 22, 2026

No patent or exclusivity listings for this strength.

Change History (1)

Recent changes detected for this application.

ADDED7/1/2026

Galderma Labs LP obtained FDA approval for Differin Epiduo (adapalene; benzoyl peroxide) under NDA 220736, supplement 001.

New: New record